Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceu… Read more
Aequus Pharmaceuticals Inc (AQSZF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.003x
Based on the latest financial reports, Aequus Pharmaceuticals Inc (AQSZF) has a cash flow conversion efficiency ratio of 0.003x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.22K) by net assets ($-6.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aequus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Aequus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aequus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aequus Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FIRSTENERGY
MU:FE7
|
0.057x |
|
PreAxia Health Care Payment Systems Inc
PINK:PAXH
|
-0.175x |
|
Quarta-Rad Inc
PINK:QURT
|
0.032x |
|
MEDICOX Co. Ltd
KQ:054180
|
-0.040x |
|
Sileon AB (publ)
F:7PN
|
N/A |
|
ANTOFAGASTA
MU:FG1
|
N/A |
|
NAM.R S.A. EO -20
F:8GQ
|
N/A |
|
Glassbridge Enterprises Inc
PINK:GLAE
|
-0.293x |
Annual Cash Flow Conversion Efficiency for Aequus Pharmaceuticals Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Aequus Pharmaceuticals Inc from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-6.45 Million | $-1.66 Million | 0.257x | -51.98% |
| 2023-12-31 | $-4.29 Million | $-2.29 Million | 0.534x | -62.24% |
| 2022-12-31 | $-1.38 Million | $-1.95 Million | 1.415x | +315.94% |
| 2021-12-31 | $1.79 Million | $-1.17 Million | -0.655x | +53.28% |
| 2020-12-31 | $573.95K | $-804.91K | -1.402x | -175.50% |
| 2019-12-31 | $-877.09K | $-1.63 Million | 1.857x | +221.37% |
| 2018-12-31 | $1.68 Million | $-2.57 Million | -1.530x | +7.45% |
| 2017-12-31 | $2.31 Million | $-3.81 Million | -1.654x | +53.13% |
| 2016-12-31 | $1.27 Million | $-4.47 Million | -3.528x | -18.07% |
| 2015-12-31 | $1.28 Million | $-3.84 Million | -2.988x | -539.50% |
| 2014-12-31 | $2.51 Million | $-1.17 Million | -0.467x | +85.03% |
| 2013-12-31 | $264.14K | $-824.68K | -3.122x | -- |